ClinicalTrials.gg

Program

Hyaluronoglucosaminidase

Also written as “HYQVIA”, “HyQvia” and “hyaluronidase”.

Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Primary Immunodeficiency Diseases · Hypersensitivity, led by 4 companies.

Furthest: phase 4, since Apr 12, 20179 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda60 open or runningphase 4since Apr 12, 2017Sep 11, 2015none ahead
Amphastar Pharmaceuticals10 open or runningphase 2since Sep 13, 2012Sep 13, 2012none ahead
Baxter Healthcare10 open or runningphase 1since Jun 26, 2007Jun 26, 2007none ahead
Shanghai Bao Pharmaceuticals10 open or runningphase 3since Sep 12, 2024Sep 12, 2024none ahead

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire and Halozyme Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2007First study: phase 1 study in HealthyNew to Baxter HealthcareBaxter Healthcare · NCT00493220 · 30 enrolled
  2. Sep 13, 2012Amphastar Pharmaceuticals’ first study: phase 2 study in HypersensitivityNew to Amphastar PharmaceuticalsAmphastar Pharmaceuticals · NCT01689363 · 253 enrolled · United States
  3. Sep 11, 2015Takeda’s first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
  4. Nov 2, 2016Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT02955355 · 85 enrolled · United States, Argentina, Brazil and more
  5. Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesTakeda · NCT03116347 · 42 enrolled · Czechia, Denmark, France and more
  6. Sep 7, 2017Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT03277313 · 44 enrolled · United States
  7. Jul 7, 2020Phase 1 study in Healthy VolunteersTakeda · NCT04578535 · 51 enrolled · United States
  8. Sep 12, 2024Shanghai Bao Pharmaceuticals’ first study: phase 3 study in HealthyNew to Shanghai Bao PharmaceuticalsShanghai Bao Pharmaceuticals · NCT06604546 · 45 enrolled · China
  9. Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06895967Healthy Volunteers · United States1CompletedTakedaJul 24, 202530
NCT06604546Healthy · China3CompletedShanghai Bao PharmaceuticalsMay 5, 202445
NCT04578535Healthy Volunteers · United States1CompletedTakedaMar 2, 202251
NCT03277313Primary Immunodeficiency Diseases · United States3CompletedTakedaJul 20, 202244
NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more4CompletedTakedaJan 15, 202142
NCT02955355Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedTakedaJul 4, 202385
NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedTakedaFeb 23, 2022138
NCT01689363Hypersensitivity · United States2CompletedAmphastar PharmaceuticalsNov 2012253
NCT00493220Healthy1CompletedBaxter HealthcareSep 200730

How it is read

Names in the registry

  • “HYQVIA”, 10 entries
  • “HyQvia”, 1 entry
  • “hyaluronidase”, 1 entry
  • “Hyaluronidase”, 1 entry
  • “SC HYLENEX and Ceftriaxone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.